Aim: The link between chemotherapy treatment and cardiotoxicity is well established, particularly for adults with blood cancers. However, it is less clear for children. This analysis aimed to compare the trajectory and mortality of children and adults who received chemotherapy for blood cancers and were subsequently hospitalized for heart failure.
INTRODUCTION
Cardiotoxicity is a well-established adverse consequence of cancer treatment, with drugs used to treat blood cancers known to have long-term cardiovascular effects including left ventricular dysfunction, myocardial ischemia, hypertension and QTc prolongation. 1, 2 These cardiotoxic agents are widely used in both children 3 and adults. 4 In the general population, the median age of heart failure (HF) diagnosis typically ranges from 70 to 83 years and is extremely uncommon in children. [5] [6] [7] [8] However, children previously treated for cancer are 5.9 times more likely to develop congestive HF than their nearest age sibling. 9 Furthermore, in the absence of overt HF in childhood, even small changes in ejection fraction from chemotherapy in childhood predispose adult survivors of childhood cancer to HF as they age. 10 Studies indicate that the pathogenesis underlying chemotherapyrelated cardiovascular changes operates on a cellular level. [11] [12] [13] Although this affects people of all ages, it is likely that the impact of chemotherapy treatment on a heart which is still developing will be different to that on a mature organ. Research has shown that cardiotoxicity can manifest up to 20 years after cancer therapy, and with improving survival rates, particularly from childhood cancer, 14, 15 this impact is likely to become even more pronounced. [16] [17] [18] This confers a need to further understand the characteristics of HF development in children previously treated for cancer.
Previous work from our research group has demonstrated that in a cohort of patients with breast or blood cancer (n = 15 987), 6 .6% of patients treated with chemotherapy were later hospitalized for HF. 19 The median age of this population was 55.0 years (interquartile range [IQR] , 44-65), and included 817 (5.1%) patients aged 18 years or under.
The purpose of this secondary analysis is to compare the characteristics and survival outcomes of children and adults in order to identify differences in the incidence, time to diagnosis and associated mortality rates.
METHODS

Study design
The parent study was a retrospective audit of linked health administration data from Queensland, Australia. Approval was granted by the Metro South Health Service District Human Research Ethics Committee (HREC/11/QPAH/600).
Data sources and data linkage
Three independent databases were linked to create the analysis database for this study: (1) the Queensland Cancer Registry (QCR), (2) the Queensland Hospital Admitted Patient Data Collection and (3) the Queensland Birth, Deaths and Marriages Registry.
The QCR houses data from all persons admitted to public and private hospitals and nursing homes with a cancer diagnosis in Queensland since 1982. 20 The initial population of interest was identified from this by selecting patients registered between January 1996 and December 2009 with a primary diagnosis of blood cancer. These dates were chosen to ensure a uniform time frame across all data sets.
The Hospital Admitted Patient Data Collection contains data on all hospital separations from any Queensland hospital permitted to admit patients. The QCR facility and Unit Record (UR) numbers were match-merged with admissions episodes from the same time period to identify those who received chemotherapy treatment. These records formed the study cohort.
The hospital admissions were further interrogated to stratify the members of the cohort with an index HF separation versus those without. The index HF episode must have occurred after the date of cancer registry entry to be included in the HF group.
Finally, the study cohort records were linked to the Queensland Birth, Deaths and Marriages database-a repository for all registered deaths in Queensland. All-cause mortality data were then extracted to complete the database. LinkageWiz software was used for probabilistic matching. 21 
Participants
The primary cancer diagnosis recorded in the QCR was used to identify blood cancers using the International Classification of Diseases 
Outcome, exposure and confounders
The primary outcomes were (1) mortality and (2) HF which occurred after blood cancer diagnosis and treatment; indicated by an index hospital admission coded for HF. Both incidence and the time to index HF admission and/or death were measured.
Possible confounders include demographic characteristics and clinical features such as income, education, medical history, chemotherapy agent and dose, and other treatment modalities such as transplantation or concurrent radiotherapy treatment.
Statistical analysis
Data management and statistical analyses were performed using STATA version 14.0 (StataCorp LP, College Station, TX, USA). Means and standard deviations (SD) for discrete and continuous data were calculated and categorical variables were presented as percentages.
Differences in demographics and cancer treatment history were analyzed for between-group differences using Fisher's exact and chisquare tests. Where continuous data were non-normally distributed, the data are presented as median (IQR)IQR and compared using appropriate non-parametric tests. Differences were considered significant at
The time-varying Cox proportional hazards regression models were used to evaluate factors associated with mortality risk during followup within groups adjusted by demographic variables and cancer treatment history (Table 2) . Hazard ratios (HR) were used to describe the probability of survival after chemotherapy treatment in each group.
The proportional hazard assumptions as well as goodness of fit of the models were also tested.
Kaplan-Meier survival curves were derived to compare the time to death from QCR registration between HF and non-HF groups for both adults and children, adjusted for sex and age using a log-rank test. 
TA B L E 1
Demographics and chemotherapy separation rates for adults (> 18 years) and children (≤18 years) who received chemotherapy for blood cancer
P-value
RESULTS
Participants
The inclusion of participants is described in accordance with the 
Demographics and clinical characteristics
Demographic information was extracted from the QCR (Table 1) .
Within the adult study population, there were significant differences in the median age at cancer diagnosis, the median number of chemotherapy admissions and the quintiles of chemotherapy admissions between those who developed HF and those who did not. However, these differences were not observed in the child population (Table 1) .
Outcome data
Of those who had an index HF admission after chemotherapy (children N = 30 and adults N = 852), 70.0% of the children compared to 46.4% of adult patients were admitted for HF within 12 months of their initial cancer diagnosis (Figure 1 ). Furthermore, a total of 83.3% of the children compared to 69.3% of adult patients were admitted for HF within the first three years of cancer diagnosis.
All-cause mortality (adjusted for age, sex and chemotherapy admissions) differed between groups, with both the child HF group (HR 4.86; 95% CI, 2.85-8.27; P < 0.001; Figure 2 ) and the adult HF group (HR 1.66; 95% CI, 1.51-1.82; P < 0.001; Figure 3 ) having a greater risk of mortality relative to the respective non-HF groups. Overall, the mortality rate was almost four times higher for children than for adults.
F I G U R E 1
Time from cancer diagnosis to the index heart failure admission in N = 30 children and N = 852 adults who underwent chemotherapy treatment for blood cancer and were later admitted for heart failure F I G U R E 2 Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving childhood cancer patients, adjusted by age, sex and number of chemotherapy separations F I G U R E 3 Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving adult cancer patients, adjusted by age, sex, marital status, country of birth and number of chemotherapy separations
The adjusted time-varying Cox proportional hazard modeling showed that both child and adult non-HF patients along with adult HF patients had an increased risk of mortality with increasing age (Table 2) .
This was not significant in the child HF patients, but this likely reflects the low numbers in this group and the HR (1.02) was higher than the HR (1.01) for the adult HF group. Although there were no differences in mortality risk by sex or number of chemotherapy admissions between the HF and non-HF child groups, there was a gender difference evident in the adult groups, with males having a higher risk of mortality for both the HF and non-HF groups than females (Table 2) .
DISCUSSION
This secondary analysis aimed to compare the characteristics and clinical outcomes of both children aged ≤18 years and adults who received chemotherapy treatment for blood cancer, and were later admitted for HF, relative to those who were not admitted for HF. The ongoing risk of HF and its associated mortality following chemotherapy have been previously described, 2-4,13 although many prior studies were based on smaller datasets or did not incorporate comprehensive longitudinal follow up. We utilized data linkage to report the adjusted, long-term survival of an unselected cohort of patients who received chemotherapy for blood cancer in a state-wide database stratified according to whether or not they were later diagnosed with HF.
The results of this study demonstrated that 3.7% of children and 11.3% of adults with chemotherapy-treated blood cancer had a later index admission for HF. These results are broadly consistent with other studies which have reported rates of cardiotoxicity following anthracycline treatment ranging from 0.9% to 26%. 23 Our results are likely to be underestimates as we are reliant on hospital admission as an indicator for HF diagnosis and therefore cannot account for either subclinical presentation or HF treated in primary care only. The maximum 13-year follow-up time of this study is insufficient to fully capture the late onset incidence of HF or HF-related death; especially in those who were treated for cancer as children, which is believed to occur up to 20 years after initial cancer treatment. 3 Although the adult population showed significant differences in both median age and number of chemotherapy separations between HF and non-HF groups, this analysis did not reach significance within the children. This is likely due to both the smaller sample size and the narrower age range of the children.
Although the proportion of the children who were admitted for HF during the study period was lower than the adult sample (3.7% vs 11.3%, respectively; Table 1 
TA B L E 2 Adjusted time-varying Cox proportional hazard models for all-cause mortality between HF and non-HF groups for adults and children
Adults N = 7522 (90.2%) Children N = 817 (9.8%) Parameter Heart Failure HR (95% CI)
P-value Non-HF HR (95% CI) P-value
Heart Failure HR (95% CI)
Age (at cancer diagnosis), years Although the current cardiac screening recommendations for individuals previously diagnosed with cancer and treated with known cardiotoxins include increased frequency of screening based on younger age at treatment and higher dosage of chemotherapy, 11,24 even these precautions do not appear to be sufficient to mediate the differences in outcomes between children and adults who subsequently develop HF.
Clinical implications
An observation from this study is the potentially high rate of early onset of HF detected in the pediatric HF population. Although the absolute numbers are small (21 of 30 children who had an HF admission had the index admission in the first 12 months after cancer diagnosis), the absolute incident rate of child HF admissions is half that seen in the adult HF population. However, comparison with an age-matched general population cohort, (calculated using unpublished admissions data from SA Health, 2010-2012) reveals that although the adult HF admission incidence in the first 12 months after cancer treatment is over 200 times, the population rate of HF admissions (adult HF 5251 per 100 000 vs population 25.3 per 100 000), the pediatric HF admission incidence is over 600 times the population rate (pediatric HF 2570 per 100 000 vs population 4.1 per 100 000). Although the higher proportion of early onset cases in the children may reflect delayed diagnosis in the adult cohort, these incident rates suggest that there may be a significant pattern of early onset HF after cancer diagnosis in children versus adults. This pattern is not explicitly reported in the trials of management of hematologic malignancies where the focus is often on the long-term cardiac risk to patients. [25] [26] [27] Furthermore, children are often excluded from clinical trials due to ethical concerns.
Current guidelines for the treatment of cancer in children recommend that cumulative anthracycline dose be limited to ≤250-300 mg/m 2 , with similar guidelines also given for other chemotherapy and radiation treatments. 2, 28 Survivorship guidelines also recommend cardiac monitoring for a number of years for both children and adults who have received cardiotoxic chemotherapy and radiotherapy. In children, recommended cardiac imaging frequency is anywhere from 1 to 5 yearly, depending on the age of the child at treatment, the cumulative chemotherapy dose and whether radiotherapy treatment was also undertaken. 28 Although the balance between providing therapeutic levels of treatment and the risk of cardiotoxicity is difficult to navigate, this analysis reinforces the need for clinicians to consider both short-term and longterm risk when deciding on chemotherapy dosage. Although adverse effects might be unavoidable in some situations, the need for early and intensive monitoring-including during treatment-especially in children is clearly necessary to reduce the severity and impact of subsequent cardiac events. Additional evidence around the optimal mode and frequency of cardiac monitoring is required to clarify best practice for each age group. Meanwhile rigorous research into the use of cardioprotectants, appropriate treatments for those with cardiac compromise, and the alternatives to cardiotoxic therapy, is also needed to build the evidence base for these therapies.
Strengths and limitations
The strength of this study is the large sample size and the linkage process which enabled the identification of outcomes not usually recorded in isolated clinical data sets. Although the results should be generalizable to any population of people who have been treated for blood cancers, there are some limitations to be considered beyond those already discussed above.
We were not able to ascertain precisely which chemotherapy treatments patients received or who also received radiotherapy. It is well known that different chemotherapy agents can have different cardiac effects, 13, 23 and that concurrent chest irradiation can also contribute to the development of cardiotoxicity, 29, 30 but these data were not available for linkage and could not be included in this analysis. Likewise, we were not able to detect or control for any preexisting conditions which may predispose individuals to the development of HF.
In the pediatric population, there was a short median follow-up time which was significantly different between the HF group and the non-HF group, with the non-HF group being followed for almost twice as long. However, this was largely explained by the shorter survival of the HF group with 50% dying within the study period compared to 14.5%
of the non-HF group. Because of the short follow-up time for many patients, and existing evidence to suggest that adverse consequences of chemotherapy can present many years after treatment, the results of this study are likely to be an underestimate of the proportion of children who developed HF.
CONCLUSION
We 
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